Meeting
2019 Gastrointestinal Cancers Symposium
Evaluation of health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC): A prospective, multicenter, open-label, double-arm trial of trifluridine/tipiracil (FTD/TPI) versus best supportive care (BSC).
Authors
Meinolf Karthaus
Klinikum Neuperlach, Munich, Germany
Meinolf Karthaus , Manfred Welslau , Jorge Riera-Knorrenschild , Albrecht Kretzschmar , Ursula Vehling-Kaiser , Rolf Mahlberg , Henning Pelz , Udo Lindig , Ludwig Fischer von Weikersthal , Volker Heinemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
2017-000292-83
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr TPS726)
DOI
10.1200/JCO.2019.37.4_suppl.TPS726
Abstract #
TPS726
Poster Bd #
Q11
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Arvind Dasari
Poster
2016 ASCO Annual Meeting
An open-label, multi-center, phase 2 study of switch maintenance with TAS-102 plus bevacizumab following oxaliplatin or irinotecan-based fluoropyrimidine-containing induction chemotherapy in patients with metastatic colorectal cancer: ALEXANDRIA study.
First Author: Mohamed E. Salem
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world treatment patterns and unmet need in patients with previously treated metastatic colorectal cancer that is not MSI-H or dMMR.
First Author: Kaushal Desai
Poster
2023 ASCO Annual Meeting
A phase 1/2a, multicenter, open-label study of CNA3103 (LGR5-targeted, autologous CAR-T cells) in patients with metastatic colorectal cancer (mCRC).
First Author: Jayesh Desai